247.91
Schlusskurs vom Vortag:
$251.31
Offen:
$254.75
24-Stunden-Volumen:
143.85K
Relative Volume:
0.50
Marktkapitalisierung:
$7.26B
Einnahmen:
$290.51M
Nettoeinkommen (Verlust:
$89.16M
KGV:
82.91
EPS:
2.99
Netto-Cashflow:
$119.18M
1W Leistung:
-2.23%
1M Leistung:
-10.28%
6M Leistung:
+72.62%
1J Leistung:
+39.83%
Krystal Biotech Inc Stock (KRYS) Company Profile
Firmenname
Krystal Biotech Inc
Sektor
Branche
Telefon
(412) 586-5830
Adresse
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
KRYS
Krystal Biotech Inc
|
248.26 | 7.35B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.59 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.28 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.43 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.75 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.52 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-05 | Eingeleitet | Jefferies | Buy |
| 2024-08-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Eingeleitet | Citigroup | Buy |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2023-02-28 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-18 | Eingeleitet | BofA Securities | Buy |
| 2021-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-04 | Eingeleitet | Evercore ISI | Outperform |
| 2019-09-24 | Eingeleitet | Goldman | Neutral |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-24 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-30 | Eingeleitet | Guggenheim | Buy |
| 2018-09-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
Assessing Krystal Biotech (KRYS) Valuation After Q4 2025 Beat And CEO Stock Sale - simplywall.st
First Trust Advisors LP Has $43.85 Million Stake in Krystal Biotech, Inc. $KRYS - MarketBeat
Capital World Investors Cuts Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 - AOL.com
8,212 Shares in Krystal Biotech, Inc. $KRYS Bought by WINTON GROUP Ltd - MarketBeat
(KRYS) Risk Channels and Responsive Allocation - Stock Traders Daily
Krystal Biotech, Inc. $KRYS Position Trimmed by GW&K Investment Management LLC - MarketBeat
Krishnan Krish S, president of Krystal Biotech, sells $6.58 million in KRYS stock - Investing.com
Krystal Biotech (NASDAQ:KRYS) Insider Sells $6,580,250.00 in Stock - MarketBeat
Krystal Biotech director Krishnan sells $6.58 million in shares By Investing.com - Investing.com South Africa
Krystal Biotech director Krishnan sells $6.58 million in shares - Investing.com
[144] Krystal Biotech, Inc. SEC Filing - Stock Titan
Segall Bryant & Hamill LLC Lowers Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech at TD Cowen Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Kathryn Romano Sells 750 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Daniel Janney Sells 11,803 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Daniel Janney sells Krystal Biotech (KRYS) shares worth $3.25 million By Investing.com - Investing.com Canada
Daniel Janney sells Krystal Biotech (KRYS) shares worth $3.25 million - Investing.com
Krystal Biotech (KRYS) CAO sells shares and receives fresh stock awards - Stock Titan
Krystal Biotech (KRYS) R&D chief logs new awards, PSU vesting and tax trades - Stock Titan
Krystal Biotech (NASDAQ: KRYS) CEO reports new equity awards and tax share surrenders - Stock Titan
Alta Bioequities linked to Krystal Biotech (KRYS) director sells 11,803 shares - Stock Titan
Krystal Biotech, Inc. $KRYS Position Increased by William Blair Investment Management LLC - MarketBeat
TD Asset Management Boosts Stake in Krystal Biotech - National Today
TD Asset Management Inc Boosts Position in Krystal Biotech, Inc. $KRYS - MarketBeat
KRYS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kathryn Romano sells 12,500 KRYS shares (NASDAQ: KRYS); 750 more vest - Stock Titan
Krystal Biotech, Inc. (KRYS) Stock Analysis: A Promising Genetic Medicine Leader with 13.63% Potential Upside - DirectorsTalk Interviews
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Krystal Biotech (KRYS) Is Up 5.6% After Stronger 2025 Profitability And EPS Growth Has The Bull Case Changed? - Sahm
Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224 - Yahoo Finance
Krystal Biotech director Janney sells shares worth $10.1 million - Investing.com
Krystal Biotech director Janney sells shares worth $10.1 million By Investing.com - Investing.com South Africa
Krystal Biotech (NASDAQ:KRYS) Director Daniel Janney Sells 700 Shares - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Director Daniel Janney Sells 37,895 Shares - MarketBeat
Daniel Janney Sells 7,741 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Krystal Biotech Director Janney Daniel Sells Over $16 Million in Company Stock - TradingView
Vanguard Group Inc. Cuts Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Assessing Krystal Biotech (KRYS) Valuation After Earnings Beat And Profitability Milestone - simplywall.st
(KRYS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Krystal Biotech (NASDAQ:KRYS) Given New $284.00 Price Target at Guggenheim - MarketBeat
Guggenheim Raises Price Target for Krystal Biotech (KRYS) to $28 - GuruFocus
Krystal Biotech slips more than 2% even after Q4 earnings and revenue top estimates - MSN
Risk On: Can Krystal Biotech Inc weather a recessionJuly 2025 Market Mood & Growth Focused Entry Reports - baoquankhu1.vn
Insider Unloading: Dino A Rossi Sells Options, Realizes $5.04M - Benzinga
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference - Bitget
Krystal Biotech execs to host TD Cowen fireside chat March 3 - Stock Titan
Krystal Biotech’s KB707 RMAT Win Opens New Lung Cancer Chapter - Yahoo Finance
Krystal Biotech Insider Sold Shares Worth $4,953,694, According to a Recent SEC Filing - marketscreener.com
Krystal Biotech (NASDAQ:KRYS) Director Sells $4,953,719.50 in Stock - MarketBeat
Krystal Biotech (KRYS) director Rossi sells shares worth $4.95 million - Investing.com
Finanzdaten der Krystal Biotech Inc-Aktie (KRYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):